**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 13364**

**Columns: Topic Highlights**

WJH 6th Anniversary Special Issues (2): Hepatocellular carcinoma

**Radioembolization with 90Yttrium microspheres in hepatocellular carcinoma: Role and perspectives**

Mosconi C *et al*. Review of recent advances in 90Y-radioembolization

Cristina Mosconi, Alberta Cappelli, Cinzia Pettinato, Rita Golfieri

**Cristina Mosconi, Alberta Cappelli, Rita Golfieri**, Radiology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum–University of Bologna, 40138 Bologna, Italy

**Cinzia Pettinato**, Medical Physics Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum–University of Bologna, 40138 Bologna, Italy

**Author contributions:** Mosconi C, Cappelli A and Pettinato C designed the research study;

Golfieri R designed and supervised the research study.

**Conflict-of-interest:** All authors declare that they have no conflicts of interest.

**Correspondence to: Cristina Mosconi MD, UO**, Radiology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum–University of Bologna, vai Albertoni 15, 40138 Bologna, Italy. cristina.mosconi@aosp.bo.it

**Telephone:** +39-051-6362598

**Fax:** +39-051-6362699

**Received:** August 19, 2014

**Peer-review started:** August 20, 2014

**First decision:** September 16, 2014

**Revised:** December 9, 2014

**Accepted:** Janurary 15, 2015

**Article in press:**

**Published online:**

**Abstract**

Transarterial radioembolization (TARE) is a form of brachytherapy in which intra-arterially injected yttrium-90-loaded microspheres serve as a source for internal radiation purposes. On the average, it produces disease control rates exceeding 80% and it is a consolidated therapy for hepatocellular carcinoma (HCC); however, current data are all based on retrospective series or non-controlled prospective studies since randomized controlled trials comparing it with the other liver-directed therapies for intermediate and locally advanced stage HCC are still underway. The data available show that TARE provides similar or even better survival rates when compared to transarterial chemoembolization (TACE). First-line TARE is best indicated for both intermediate-stage patients (staged according to the Barcelona Clinic Liver Cancer staging classification) who have lesions which respond poorly to TACE due to multiple tumors or a large tumor burden, and for locally advanced-stage patients with solitary tumors, and segmental or lobar portal vein tumor thrombosis. In addition, emerging data have suggested the use of TARE in patients who are classified slightly beyond the Milan criteria regarding radical treatment for downstaging purposes. As a second-line treatment, TARE can also be applied in patients progressing to TACE or sorafenib; a large number of phase II/III trials are ongoing with the purpose of evaluating the best association with systemic therapies. Transarterial radioembolization is very well tolerated and has a low rate of complications which are mainly related to unintended non-target tissue irradiation, including the surrounding liver parenchyma. The complications can be additionally reduced by accurate patient selection and a strict pre-treatment evaluation including dosimetry and assessment of the vascular anatomy. Since a correct treatment algorithm for potential TARE candidates is not clear and standardized, this comprehensive review analyzes the best selection criteria for patients who really benefit from TARE and also the new advances of this therapy, which can be a very important weapon against HCC.

**Key words**: Radioembolization; Yttrium-90; Hepatocellular carcinoma

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Transarterial radioembolization (TARE) is a consolidated therapy for hepatocellular carcinoma. TARE is best indicated for both intermediate-stage patients (according to the Barcelona Clinic Liver Cancer staging classification) who have lesions which respond poorly to Chemoembolization due to multiple tumors or large tumor burden, and for locally advanced-stage patients with solitary tumors, and segmental or lobar portal vein tumor thrombosis. Moreover, emerging data have suggested the use of TARE in patients who are classified slightly beyond the Milan criteria regarding radical treatment for downstaging purposes. This review analyzes the best selection criteria for patients who really benefit from TARE.

Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with 90Yttrium microspheres in hepatocellular carcinoma: Role and perspectives. *World J Hepatol* 2015; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide, with more than 700000 cases diagnosed yearly[1] and is the third most common cause of cancer-related mortality[2,3].

The current staging system, the Barcelona Clinic Liver Cancer (BCLC) staging classification recommends transarterial chemoembolization (TACE) as the standard of care for intermediate HCC (BCLC-B stage) and systemic therapies for advanced HCC (BCLC-C stage)[4,5].

Albeit a systematic review by Llovet *et al*[6] has reported an increased survival rate in patients treated with TACE; its low efficacy has however been demonstrated in large (> 5cm) and in multinodular tumors[7-10]. A multicentric Japanese[11] study showed a significant decrease in 3-year survival after superselective TACE for lesions > 5 cm and multiple lesions (four or more) and an inverse correlation between survival and tumor size and number; in fact they obtained, in group of Child-Pugh A, the highest 3-year survival (80%) in patients with single lesion ≤ 2 cm and the lowest 3-year survival (30%) in patients with more than 4 lesions ≥ 5.1 cm and, in the group of Child-Pugh B, highest 3-year survival (65%) in patients with 2 lesions ≤ 2 cm, and the lowest (0%) in patients with three lesions ≥ 5.1 cm.

Regarding Sorafenib, a receptor tyrosine kinase inhibitor, two large randomized trials[12,13], together with other studies[14-16], have reported a benefit in terms of survival rate in advanced HCC with distant metastasis and/or vascular invasion. However, in a subsequent subanalysis of these trials, the tolerability of Sorafenib was revealed to be suboptimal; it was down-dosed in more than half of the patients and interrupted in 45% of patients due to severe adverse events (AEs) or liver function deterioration[17].

This scenario has led to new therapies for the best management of intermediate/advanced-stage HCC and, in this setting, available data have shown that transarterial radioembolization (TARE) could be an effective therapeutic option.

In the present review, the recent results of TARE regarding technical aspect, tumor response, survival rates, adverse events and safety have been summarized. The potency of TARE has been focused on, with the aim of providing its optimal use in daily practice in different settings and for conducting effective clinical trials on patients with intermediate/locally advanced-stage HCC. The new dosimetric advances affecting tumor response and safety have also been reviewed and the future direction for TARE has also been discussed.

TECHNICAL ASPECTS

The aim of TARE is to selectively target a high radiation dose to tumors within the liver, regardless of their cell of origin or location, while radiation to the normal liver is kept at tolerable levels. This is achieved by the preferential deposition of microspheres carrying a high energy radiation source [yttrium-90 (90Y), 0.97 MeV], a beta-emitter, within the tumor capillary bed so that a tumoricidal dose of radiation (100 to 1000+ Gy) is absorbed over a limited range (mean tissue penetration 2.5 mm; maximum 11 mm) for a limited time; 90Y decays to stable zirconium-90 with an average half-life of 2.67 d (64.2 h)[18].

Transarterial radioembolization is defined as the injection of micron-sized embolic particles loaded with a radioisotope by means of percutaneous transarterial techniques in order to deliver high focal doses of radiation to tumors.

Transarterial radioembolization is similar to TACE as regards the technical aspects of the procedure since both require selective or superselective catheterization of the tumor-feeding vessels; however, both the principles and the mode of action of radioembolization are fundamentally different from conventional embolization or TACE. For the latter to be effective, the vessels feeding the tumor are filled with chemotherapeutic agents and are subsequently embolized with particles to ensure a static, ischemic environment in order to maximize exposure to those agents, and to promote ischemic necrosis. In contrast, for intra-arterial radioembolization to be effective, optimal perfusion and blood flow are required to allow the generation of free radicals by ionization of the water molecules near the DNA of the tumor cells. In the presence of normal oxygen tension, permanent DNA damage is caused to one or both DNA strands, and apoptosis is initiated or reproductive death is eventually achieved[18]. Maximal cytoreduction by radiation requires not only normal oxygen tension in the target cells but also sufficient microsphere coverage of the tumor nodule to avoid gaps in cumulative radiation due to crossfire ‘‘cold spots’’ or a low total dose of radiation in the tumor[18]. For this reason, the particles used for radioembolization must be small enough (~20 to 40 mm) to allow optimal access into the tumor nodules and deposition within the tumor plexus, without creating ischemia, but large enough to prevent the passage of microspheres through the capillary bed into the venous circulation leaving the liver.

Two types of microspheres loaded with 90Y are commercially available, one made of resin (SIR-Spheres; Sirtex Medical, Sidney, N.S.W., Australia) and an alternative made of glass (TheraSpheres, MDS Nordion, Toronto, Ont, Canada); the differences include the amount of activity contained in each microsphere and the number of microspheres injected in a single treatment (< 5 million to 10–30 million for glass and resin microspheres, respectively); however, their efficacy, toxicity and clinical outcome are similar (Table 1).

An HCC is a radiosensitive tumor[19] but external beam radiation therapy (EBRT) is not widely used due to severe liver toxicity [radiation induced liver disease (RILD)] when the dose absorbed by the liver is greater than 35 Gy[20,21] and lower doses, in order to spare the liver parenchyma, do not obtain a tumoricidal effect; an effective dose must exceed 70Gy[22,23].

In both resin and glass microspheres, the primary mechanism of action is to the result of a localized radiotherapeutic effect (brachytherapy) rather than to microvascular embolization and tumor ischemia[24-26]. The radiation dose absorbed depends on the microsphere distribution within the tumor, mainly resulting from the arterial hepatic hemodynamic and tumor vascularization. In this way, tumors can be exposed to a higher radiation dose than with EBRT. In TARE, dosimetry planning, the administration and delivery of the radiation, modification of the dose on the basis of tumor and hepatic volume, and the knowledge required regarding radiation effects on tissue make this therapy a brachytherapy procedure as well.

**TARE PROCEDURE**

***Patient selection***

The specific technical aspects of the TARE procedure have recently been addressed by an International Working Group[27],and a detailed review of the methodological and technical aspects of the procedure was undertaken by Salem *et al*[28].

A multidisciplinary team consisting of professionals from interventional radiology, hepatology, medical, surgical and radiation oncology, and nuclear medicine is involved in selecting patients suitable for radioembolization. The patients are selected according to the following criteria:

**Inclusion criteria**: (1) confirmed diagnosis of unresectable HCC; (2) age > 18 years; (3) Eastern Cooperative Oncology Group performance status ≤ 2; (4) adequate hematologic parameters (granulocyte count < 1.5 x 109/L, platelet count > 60 x 109/L), renal function (serum creatinine level < 2.0 mg/dL) and liver function (serum total bilirubin level < 2.0 mg/dL); and (5) the ability to undergo angiography and selective visceral catheterization. The majority of patients have a Child-Pugh score ≤ 7 even though a Child-Pugh score > 7 is not an absolute contraindication.

**exclusion criteria**: (1) any other liver-directed therapy planned for cancer treatment; (2) uncorrectable flow to the gastrointestinal tract; (3) lung shunting > 20% (resin microspheres) or estimated radiation doses to the lungs > 30 Gy (with a single administration) or 50 Gy (with multiple administrations); and (4) significant extrahepatic disease.

In cirrhotic patients, the tumor volume has to be ≤ 50% of the total liver volume while, in patients with normal liver function, the tumor volume should not exceed 70% of the total liver volume.

***Pre-treatment Evaluation***

All patients undergo pretreatment assessment, consisting of history, and a laboratory and imaging work-up, approximately 1/3 wk before the first planned treatment. Pretreatment cross sectional imaging is essential for treatment planning and post-treatment response assessment.

Treatment with 90Y microspheres is a 2-stage process involving an extensive work-up procedure to assess the appropriateness of the patient for treatment and to prepare the liver for radiation treatment, and the treatment procedure itself[29]. The pretreatmentwork-up includes:

**Imaging work-up**: 3-phase contrast computed tomography (CT) and/or gadolinium-enhanced magnetic resonance imaging (MRI) of the liver should be conducted for the assessment of tumor and non-tumor volume, portal vein patency and the extent of extrahepatic disease (Figure 1A-1B).

**Pre-treatment Angiography**: given the high propensity for arterial variants and hepatic tumors to exhibit arteriovenous shunting, all patients being evaluated for 90Y must undergo pretreatment angiography (Figure 1C)[30]. This permits tailoring the treatment plan according to each patient’s individual anatomy and helps to assess the possibility of any inadvertent spread of the microspheres to non-target organs; this can be mitigated by the prophylactic embolization of aberrant vessels to non-hepatic targets[30]. The superior mesenteric and celiac trunk angiograms provide the interventional radiologists an opportunity to study the hepatic vascular anatomy. The patency of the portal vein and the presence of arterio-portal shunting are also assessed. In some cases, prophylactic embolization of the gastroduodenal artery and right gastric artery is recommended as a safe and efficacious mode of minimizing the risks of hepatoenteric flow since this can lead to the inadvertent deposition of microspheres in the gastrointestinal tract causing severe ulcers which are highly symptomatic and difficult to manage[31]. Other vessels which need to be investigated and potentially embolized are the falciform, inferior esophageal, left inferior phrenic, accessory left gastric, supraduodenal and retroduodenal arteries. Diagnostic angiography is essential for ensuring that the blood supply to the tumor(s) has been adequately identified since incomplete identification of the blood supply to the tumor may lead to incomplete targeting and treatment. This facilitates accurate calculations of the target volume.

**99mTc-MAA scintigraphy***:* one of the most important complications related to TARE is the possible deposition of microspheres in extrahepatic sites, in particular into the lungs due to hepato-pulmonary shunts. Since doses to the lungs can represent a limitation of the 90Y injected activity, evaluation of the lung shunt is mandatory before TARE (Figure 1D**)**. Just after the pre-treatment angiography 150-200 MBq of 99mTc labeled macroaggregated albumin (99mTc-MAA) are intra-arterially administered into the arterial branch selected for the treatment. Macroaggregated albumin particles, considered a surrogate of microspheres, can be used to simulate their distribution to the liver, lungs and, possibly, the extrahepatic abdominal organs. The lung shunt fraction is evaluated by means of antero-posterior planar or whole body scintigraphy while the 3D distributions of the microspheres inside the tumor and normal liver can be evaluated by acquiring single photon emission computed tomography (SPECT) images[32].Scintigraphy is usually performed within one hour after the injection of 99mTc-MAA in order to avoid redistribution of free technetium and MAA particles, causing false-positive extrahepatic findings.

The lung shunt fraction is obtained by planar 99mTc-MAA imaging as follows:



where:

(Total counts)lungs is the geometric mean of the total counts in a Region of Interest (ROI) positioned on the lungs in the anterior and posterior views of the 99mTc-MAA scan;

(Total counts)liver is the geometric mean of the total counts in a ROI positioned on the liver in the anterior and posterior views of the 99mTc-MAA scan.

The dose absorbed in the lungs, due to the shunt, can be calculated using the following formula:



A radiation absorbed dose limit of 30 Gy per radioembolization treatment session is recommended[33]. The published upper limit for hepatopulmonary shunt fraction is 20% for resin-based microspheres (SIR-Spheres; Sirtex)[31].

***90Y treatment***

The 90Y treatment is carried out using well-known guidelines[27,28,34]based on the experience of more than 900 90Y infusions carried out over a 5-year period.

The tumor is approached under fluoroscopic guidance; the first part of the procedure is similar to the pretreatment angiography after which the activity vial is injected into the vessel feeding the tumor. The device for administering the 90Y is designed to minimize the radiation exposure of the personnel involved in the procedure. A physicist is present throughout the procedure to ensure that proper protocols are followed in order to minimize accidental radiation exposure. In some hospitals, immediately after the treatment, a Bremsstrahlung (gamma) scan or positron emission tomography-CT is performed to evaluate 90Y distribution.

**DOSIMETRY**

The main goal of TARE is to deliver a curative therapeutic dose to the tumor while sparing normal tissues[35]. Personalized treatment planning is desirable for TARE and can be carried out using 99mTc-MAA SPECT images and volumes obtained from CT scans. The image fusion of the CT and the SPECT images can help in the delineation of volumes involved in the treatment.

An important limitation of TARE is the dose to the normal liver because an excessive dose to the normal parenchyma could induce radiation hepatitis and liver failure[36]. The spatial distribution of the microspheres is crucial and may be very different for the two types of spheres. When using resin microspheres, the dose absorbed by the normal liver should be kept lower than 40 Gy to minimize the risk of liver failure, especially in patients having compromised liver function[36]. Although personalized dosimetry would be the best approach to TARE, it has not been standardized and is often not attainable.

For these reasons, the majority of TARE treatments are performed calculating the injected activity based on empiric formulas suggested by the manufacturers instead of following scrupulous dosimetric formalism. In the following paragraphs, the standard methods for activity assessment have been briefly described for both glass and resin microspheres.

***Glass microspheres***

The activity determination for glass microspheres, proposed by the manufacturer (TheraSphere Yttrium-90 Glass Microspheres Users Manual. BTG cercare nuovo indirizzo), is based on a nominal target dose (80–150 Gy) to the treated mass (M), which can be measured by CT images. This approach assumes a uniform distribution of the microspheres throughout the treated volume, including the tumor and the normal parenchyma:



Lung dose should be kept to less than 30 Gy for a single injection and less than 50 Gy as a cumulative dose for multiple injections[37].

Using the above formula, the dose delivered to the tumor is not known; however, going on the assumption that tumors have an higher vascularity as compared to the normal parenchyma, it is reasonable to predict that the prescribed dose be at least that which is absorbed by the tumor in order to prevent liver fibrosis.

***Resin microspheres***

Two methods are proposed by SIRTEX to determine the activity of 90Y to be injected: the empiric method and the Body Surface Area (BSA) method [38].

The empiric method suggests a standard amount of activity based on tumor involvement only, considering three varying degrees of tumor involvement:

Tumor ≤ 25% of the total mass of the liver by CT scan = 2 GBq whole-liver delivery;

Tumor ≥ 25% but ≤ 50% of liver mass by CT scan = 2.5 GBq whole-liver delivery;

Tumor ≥ 50% of liver mass by CT scan = 3 GBq for whole liver delivery;

It is important to point out that this method is not recommended by the scientific community[39].

The BSA method is a variant of the empiric method which calculates the injected activity, taking into account the patient’s BSA and the fraction of liver volume involved by the tumor:



Where: BSA(m2) = 0.20247 \* height (m) 0.725 \* weight (kg) 0.425

The BSA formula is considered safe for patients with compromised liver function or for particularly small patients. A reduction of the amount of activity up to 20% is recommended for lung shunts greater than 15%.

***Dosimetric approach***

The empiric methods suggested by both manufacturers do not represent a real dosimetric approach to the treatment because the distribution of the 90Y microspheres and the uptake ratio between the tumor and the normal parenchyma are never considered, thus preventing any accurate dosimetric evaluation.

A dosimetric approach based on Medical Internal radiation Dosimetry (MIRD) formalism was proposed by SIRTEX as a “partition model” and has been formalized with MIRD equations by Gulec and colleagues[40]. The MIRD formalism is based on the determination of the fraction of activity (fractional uptake) which is trapped by the tumor, normal liver and lungs, respectively, by the masses of each compartment which are calculated using CT images. The fractional uptake, representing the fraction of activity reaching each compartment, is measured by 99mTc-MAA SPECT images, calculating the tumor to liver ratio and the lung shunt fraction. Because the dose to the normal parenchyma is the most important limiting factor, the administered activity can be calculated as the activity delivering the selected nominal dose to the liver, as follows:



where:

A(GBq) is the 90Y injected activity;

D(Gy) is the nominal dose to the liver;

M(Kg) is the liver mass;

and 50 is a constant which depends on the physical characteristics of 90Y.

Once the fraction of activity reaching each compartment/tissue is measured, the corresponding absorbed dose is evaluated using the following formula:



The 99mTc-MAA particles are considered a surrogate of the microspheres, and their distribution inside tissues is representative of the microsphere distribution. It is very important to point out that, using 99mTc-MAA SPECT images, it is possible to carry out provisional dosimetry before the 90Y infusion, although it presents several limitations. In particular, the major limitations of this approach are the different size and specific gravity of 99mTc-MAA and the 90Y microspheres, the different volume and velocity of injection, the reproducibility of the exact site of injection and the hemodynamic conditions inside the tumor which can be considerably different between the 99mTc-MAA and the 90Y treatments. Furthermore, the MIRD approach assumes the uniform distribution of the microspheres and measures average doses while, especially in tumor masses, the dose is strongly dependent on heterogeneous vessel density.

However, despite the limitations listed above, the higher mean dose absorbed by the tumor masses, calculated with 99mTc-MAA SPECT images, was predictive of a better tumor response in patients affected by HCC for both resin[41] and glass microsphere[35] treatments.

Furthermore, the intrinsic differences between the two types of microspheres and, in particular, their different numbers and specific activities, are responsible for the different distribution of the microspheres inside the tissues, more uniform for resin than for glass microspheres. Consequently, the published data regarding dosimetry have reported higher values of the tumor dose response for glass microspheres than for resin microspheres[42].

**POST-TREATMENT ASSESSMENT AND FOLLOW-UP**

To monitor tumor response and to identify any toxicity, clinical, laboratory and radiologic follow-ups are necessary. A regular follow-up includes liver function tests, a complete blood count, tumor marker analysis and cross-sectional imaging (CT and/or MRI) one month post-treatment and then every three months.

Imaging after TARE is required to monitor the tumor response but it is not always easy to interpret. Imaging usually shows a change in both the appearance of the tumor and the surrounding liver. Since the effect of the radiation may not be manifested until after 30 d, imaging at 1 mo after the procedure is usually not representative of the tumor response(Figure 1E-F). However, a common early feature is the appearance of rim enhancement surrounding the lesion; this is an early sign of a fibrotic capsule and it is fundamental not to erroneously consider it as a residual tumor[43]. Instead, in a period ranging from 8 to 12 wk after TARE (Figure 1G-H), there is noticeable tumor shrinkage and the parenchyma also becomes atrophic as a consequence of hepatic fibrosis and capsular retraction of the treated area; atrophy of the treated area induces a compensatory hypertrophy of the contralateral lobe especiallyafter lobar procedures (rather than after a segmental or subsegmental approach). Another common feature is the appearance of transient perfusion abnormalities in the treated area, which should be differentiated from residual or recurrent tumors. Furthermore, transient hypoattenuating perivascular edema near the hepatic and portal veins can also be observed on imaging.

Computed tomography is capable of identifying changes in the size of the lesions, alterations in vascularity and enhancement; the appearance of new intra or extrahepatic lesions are well defined with this technique but may limit the capability of documenting the tumor necrosis.

Magnetic resonance imaging, especially using diffusion-weighted imaging (DW-MRI) and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid imaging (Gd-EOB-DTPA-MRI) identifies necrosis and cell death[44] earlier (6–8 wk post-procedure in some cases) and better than CT[34,45].

Regarding the assessment of treatment response, the clinical studies conducted have mainly used modified Response Evaluation Criteria in Solid Tumors[46] or the European Association for the Study of the Liver (EASL) criteria, the former measuring the diameter and the latter the area of the enhancing tumor[47].

**RESPONSE AND SURVIVAL ACCORDING TO TUMOR STAGES**

***Tumor response after treatment***

The benefits of 90Y TARE in patients with HCC have been widely described[48-53] .Current data report a response rate which varies among published studies, mainly due to the heterogeneous populations enrolled (Table 2).

In an early study[54], a 50% reduction in tumor volume was reported in 19 (26.7%) out of 71 patients after the first treatment. More recently, a German multicenter study[55] (carried out on 108 patients) reported complete response (CR) in 2 (3%) patients, partial response in 23 (37%) and stable disease in 33 (53%) patients 3 mo after treatment, using the EASL criteria.

In a European prospective study involving 52 patients with a median follow-up of 36 mo, Mazzaferro *at al*[56] reported an objective response and a disease control rate of 40.4% and 78.8%, respectively, according to the EASL response criteria; there was a CR in 5 patients (9.6% of cases).

***TARE in intermediate- and early-stage patients***

According to the BCLC staging system recommendation, in the intermediate stages, TACE is the first-line therapy for asymptomatic patients with multinodular unresectable HCC[6,57-59].However, these data come from trials which enrolled a large number of patients in the early stage or patients in the intermediate stage but with single-lobe involvement. Moreover, the TACE procedure was performed with very different modalities all over the world; the above-mentioned reasons explain the wide differences in the 2-year survival rates observed in prospective randomized trials (24%–63%) as well as in retrospective series (11%–47%)[8].

Patients in intermediate-stage HCC who are treated with TARE as a first-line therapy are generally patients with a normal performance status for whom TACE is not suitable due to voluminous disease with more than 5 nodules in both lobes or a single large nodule. In these patients (BCLC-B stage), survival was approximately 15.4-16.6 mo[8],not very different from the median overall survival (OS) of 15.6-17.4 mo observed in patients treated with TACE[60-62]. Survival was even better after TARE than after TACE in patients who were ideal candidates for TACE as reported by Sangro *et al*[8] with a median OS of 22.8 mo in patients with 1-5 nodules and 23.2 mo for those with unilobar disease.

It has been widely reported that TACE is not effective for large tumors, especially for tumors > 5 cm[10] or in the presence of multiple satellite nodules; in this setting, TARE could be the first line treatment.

Numerous studies have compared TARE to TACE in matched patient cohorts; Table 3 summarizes the largest and the most noteworthy series reported in the literature.

In a recent study, Salem *et al*[63], comparing TARE and TACE in the entire cohort of patients achieved a median OS for TACE and TARE patients (53% intermediate-stage HCC and 35% early-stage HCC) which did not significantly differ (17.4 mo for the TACE group and 20.5 mo for the TARE group); moreover the same study, analyzing only the survival of the BCLC B group, showed similar results between TARE and TACE (17.5 mo *vs* 17.2 mo, *P* = 0.42). Lance *et al*[64], in a recent retrospective study, did not report any significant differences in survival when comparing 38 patients treated with TARE and 35 treated with TACE (median 8.0 mo *vs* 10.3 mo, *P* = 0.33, respectively).

However, significant data regarding comparison between TARE and TACE are lacking because of the well-known heterogeneity of the BCLC-B stage, which includes different tumor characteristics in terms of tumor number and size[65]; at the moment, in fact, the data available are not sufficient to demonstrate a significant difference between these two therapies. In order to power a head-to-head equivalence trial with TACE having overall survival as the main endpoint, more than 1000 patients would have to be recruited, and this would represent too large a sample, even for a multicenter study[63].

Moreover, it is also necessary to evaluate the cost-effectiveness of these two therapies considering, on the one hand, the higher cost of TARE and, on the other hand, the longer hospital stay and the cumulative charges involved in repeated TACE procedures.

The shorter time to tumor response and the longer time to tumor progression (TTP) after TARE as compared to TACE are two important considerations; these data suggest a potential advantage of using TARE as a bridge therapy in patients waiting for liver transplantation (LT)[63].

In fact,in the early stage,90Y treatment is most usually employed as a bridge to liver transplantation. Riaz *et al*[66] haverecently demonstrated that none of the 15 patients treated with TARE prior to LT progressed from United Network for Organ Sharing T2 to T3, and 8 out of 10 were downstaged from the T3 to the T2 stage; moreover, histology showed 100% necrosis in 89% of the lesions < 3 cm and 65% of the lesions 3-5 cm in size. The same authors and others had previously analyzed[67,68] similar data in patients treated with TACE prior to LT, showing 35%-57% complete necrosis in lesions < 3 cm and 17%-42% in lesions 3-5 cm in size[67,9]. A retrospective analysis by Lewandowski *et al*[69] showed that TARE achieved better downstaging than TACE (58% *vs* 31%, *P* = 0.023) in patients with HCC beyond the Milan criteria, among which as many as two-thirds were downstaged.

Gramenzi *et al*[70] have very recently reported that, among the patients treated with TARE in the series analyzed, two patients were successfully downstaged, free from HCC recurrence and listed for LT.

***TARE in advanced stage patients***

Sorafenib is the mainstay for treating advanced HCC, defined by the presence of vascular invasion, extrahepatic disease or deteriorated performance status in a patient with at least partially preserved liver function; it has been shown to improve survival in these patients with or without portal vein tumor thrombosis (PVTT)[12,13] ; however, it is not without severe side effects.

Patients in the advanced stage treated by radioembolization have median overall survivals ranging from 6–10 mo[71] very similar to the 6.5-10.7 mo of the SHARP and Asia-Pacific populations. Due to the lack of significant macroembolic effect causing liver decompensation, PVTT is not a contraindication for radioembolization; however, prognosis is closely correlated to the PVTT extension; in fact, patients with main PVTT have a poor prognosis (OS ranging from 3 to 6 mo) as compared to the patients with segmentary or lobar PVTT (OS ranging from 10 to 14 mo).Patients with PVTT and Child-Pugh B have a median survival of 2-5 modue to liver decompensation[72].

Currently, there is increasing evidence that TARE can be delivered safely and effectively in patients with lobar or segmentay PVTT. Table 4 reports several studies with a median OS rate of approximately 10 mo. Therefore it is evident that TARE in BCLC-C stage patients with PVTT could be an alternative to sorafenib but a phase III trial comparing TARE with sorafenib in locally advanced HCC would be necessary to define the role of these two therapeutic strategies in advanced-stage HCC.

However, to date, only one retrospective series with a propensity analysis[70] has compared the outcomes of two groups of patients treated with TARE and Sorafenib, and it showed that these therapies provided similar survival; the median OS of the Sorafenib arm was 13.1 mo (95%CI: 1.2-25.9) and of the TARE arm 11.2 mo (95%CI: 6.7-15.7; *P* = 0.392) but only in the TARE arm were 2 patients fully downstaged to LT.

Even if liver failure or intrahepatic tumor growth are the reasons for nearly 90% of deaths among HCC patients, the presence of extrahepatic disease has however been demonstrated to have a negative impact on survival after TARE; the median OS was 7.4 mo in a European series[72] and 5.4 mo in a United States (US) series[71]. Evaluating this aspect, the fundamental aim of the emerging studies was the combination of TARE and sorafenib[73,74]. There was only one study which evaluated the combination of TARE with sorafenib published by Kulik *et al*[75]; this randomized study compared the safety of combining TARE with sorafenib to TARE alone in 20 patients intended for LT; seventeen patients underwent liver transplantation, 9 patients in the TARE group and 8 in the other arm. This study showed that the combination of sorafenib and TARE did not appear to influence complete pathological necrosis and had similar survival rates (70% and 72% at 3 years); moreover, the combination was associated with more peri-transplant biliary complications and potentially trended towards more acute rejections.

**SAFETY, TOLERABILITY AND TOXICITY**

The safety of TARE in HCC has been well documented in the literature[54,76,77]. In fact, this therapy has excellent tolerability and a low incidence of complications resulting from the irradiation of non-target tissues, including the non-tumor liver compartment. The incidence of complications can be additionally reduced by patient selection and by rigorous pretreatment assessment, including dosimetry models and the thoroughness of the technique applied[66].

The main complications occurring after radioembolization can be broadly classified into the following groups: postradioembolization syndrome, hepatic dysfunction, biliary sequelae, GI ulceration, radiation pneumonitis and lymphopenia[66]. The majority of current reports in the literature use the Common Toxicity Criteria of Adverse Events 3.0

The most common side effect is postradioembolization syndrome; its incidence ranges from 20% to 55%[50,78]. Postradioembolization syndrome consists of the following clinical symptoms: fatigue (54%-61%), nausea and vomiting (20%-32%), fever (3%-12%), abdominal discomfort (23%-56%), cachexia and anorexia[8,71]. The degree of symptoms is reported to be less severe when compared to TACE[71] and, after TARE, they are generally transient.

RILD is defined by the presence of jaundice, mild ascites, a marked increase in bilirubin and alkaline phosphatase, no change in transaminase levels and LFTs, the latter ranging from 15% to 20%[36]. It is described as a form of sinusoidal obstruction syndrome which usually occurs 4-8 wk after TARE[36]; Sangro *et al*[36], who described it for the first time, performed in some patients affected by suspected RILD the liver biopsy that showed extensive sinusoidal congestion affecting perivenular areas with focal hepatic atrophy, areas of necrosis around central veins with fresh thrombosis, and some cholestasis in periportal areas. These findings were consistent with hepatic veno-occlusive disease. RILD ranges from 0%–4%[18]; however, it is difficult to establish the actual incidence of this complication, mainly due to the fact that the majority of published series report the changes in laboratory tests over different periods of time (from 30 d to the entire follow-up period).

The incidence of biliary sequelae after radioembolization is less than 10%[66]. These complications may result from the microembolic effect of the therapy or radiation-induced injury to the biliary structures. The majority of biliary complications are not manifested clinically; clinical correlation with imaging findings is recommended.

According to Atassi *et al*[79], < 2% of patients required drainage of bilomas, treatment of abscesses and cholecystectomies. However, the treatment is not recommended in patients with main biliary duct obstruction or stenting. Radiation cholecystitis requiring surgical intervention occurs in less than 1% of cases[66].

Transarterial radioembolization can lead to severe toxic effects as a result of the non-targeted distribution of 90Y-microspheres, such as radiation-induced gastroduodenal ulcerations (less than 5% if proper percutaneous techniques are used)[66]. Severe epigastric pain after treatment should be aggressively managed as early management could prevent more serious complications from occurring. Endoscopy may be required to confirm the diagnosis. Cases refractory to proton pump inhibitors may require surgical management. As opposed to a normal ulcer which develops at the mucosal surface, 90Y-induced ulcers originate from the serosal surface. This may theoretically decrease the ability of the ulcer to heal and complicate the surgical field from scars/adhesions should surgery be required. Pretreatment angiography is essential to identify vessels which may supply the GI tract. However, gastrointestinal toxicities can be avoided by using meticulous techniques.

Pneumonitis is a rare event due to the mandatory quantification of pretreatment lung shunting[36,37]. Monitoring of the development of pneumonitis is necessary if the lung shunt fraction is greater than 13%[37]. If standard dosimetry models are used, the incidence of radiation pneumonitis is well below 1%[66]. Radiation pneumonitis manifests as a restrictive ventilatory dysfunction. It is radiologically seen as having a bat-wing appearance on chest CT. Lung doses less than 30 Gy per treatment and less than 50q Gy cumulatively are recommended.

Mild to moderate lymphopenia may be experienced in patients after TARE, but an association with increased susceptibility to infections has not been demonstrated[48].

Other side effects to be expected after treatment are a transient elevation in liver function tests, specifically in alkaline phosphatase, bilirubin and alanine transferase levels[36,80] .

In a retrospective analysis involving 325 patients conducted on the database of the European Network on Radioembolization with yttrium-90 resin microspheres study group[81], the clinical outcomes of elderly as compared to younger patients were evaluated. The authors showed that TARE was equally well tolerated in all cohorts and that the common procedure-related AEs were of mild-to-moderate intensity and of short duration. Moreover, in the elderly cohort (≥ 75 years), no AEs were of grades ≥ 3. The difference in the occurrence of severe AEs was not statistically significant in the two cohorts. Gastrointestinal ulceration was predominantly mild or moderately severe in both the younger and the elderly patients (*P* = 0.320); severe increases in total bilirubin (to grade ≥ 3) at 3 mo as compared to baseline were observed in 4.3% and 6.9% of the elderly and the younger populations, respectively (*P* = 0.432) and in 4.2% of the very elderly population. A greater number of elderly patients experienced hypoalbuminemia (*P* = 0.018) and elevated alanine transaminase (*P* = 0.015) at 3 mo, although these changes were mild (grades 1–2).

**CONCLUSIONS AND FUTURE PERSPECTIVES**

Three categories of patients are potential candidates for 90Y-TARE: (1) patients in the intermediate stage who are not good candidates for TACE due to numerous or bulky tumors; (2) patients in the advanced stage with solitary HCC tumors and segmental or lobar PVTT; and (3) patients with HCC in potential downstaging for a radical approach.

Indeed, the European Society for Medical Oncology[82], the European Society of Digestive Oncology[83], and the National Comprehensive Cancer Network have recently included 90Y-TARE in their guidelines as a ‘bridge’ option before other treatment modalities (partial hepatectomy, LT) as the principal therapy for patients with diffuse intrahepatic tumor spread or as an alternative to TACE in selected patients with contraindications for TACE[81,83]. Moreover, the Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting[84] stated that TARE may be used in selected patients with HCC without extrahepatic disease who are amenable to radical therapies.

Nevertheless, the American Association for the Study of Liver Disease[85], EASL and the European Organization for Research and Treatment of Cancer do not include TARE in their guidelines.

For this reasons, relevant clinical trials are now underway to establish the precise role of TARE in the treatment of HCC, in particular multicenter RCTs regarding both the intermediate and the advanced stages of HCC.

The PREMIERE trial (NCT00956930), a US randomized trial, compares TARE with radiofrequency ablation, TACE or their combination in patients with unresectable HCC and well preserved liver function. To date, as described above, no significant differences between TACE and TARE have been found in terms of survival rates, but TARE seems to be significantly better tolerated regarding post-procedural abdominal pain, length of hospital stay and post-embolization syndrome.

Two important multicenter randomized-controlled trials in advanced-stage patients are the Asia-Pacific SIRveNIB trial (NCT 01126645) and the European SORAMIC trial (NCT01126645); they compare TARE and Sorafenib in HCC patients without extrahepatic disease who are not suitable for TACE and also in HCC patients with extrahepatic disease. The trials are ongoing but preliminary results report that TARE should be considered as good an option as sorafenib in the same setting of patients. The YES-P trial (NCT 00537514) has recently begun; it is a large prospective randomized clinical trial comparing TARE with glass microspheres (TheraSphere®) *vs* sorafenib for the treatment of advanced HCC with PVTT, involving up to 25 sites in Europe, Asia and North America.

Another important aspect to evaluate is the quality of life after TARE; Salem *et al*[86] have recently compared the Quality of life (QoL) of HCC patients treated with TACE (29 patients) *vs* those treated with TARE (27 patients), using the FACT-Hep questionnaire (a 45-item self-report instrument specifically designed with patient and clinician input to measure health-related QoL in patients with hepatobiliary cancer)[87].

They did not observe any significant differences in overall FACT-Hep health-related QoL scores between the two groups, even if the TARE group had significant improvement in several aspects of QoL as compared to the TACE group. Currently, there is only one ongoing European randomized trial, the SIRTACE study (NCT00867750), which analyses the quality of life after TACE and TARE.

Finally, it is very important not to forget the cost of the TARE procedure; a recent study by Kooby *et al*[88], comparing the costs of TARE to those of TACE, has demonstrated that the first is less expensive than multiple TACE sessions, especially if drug-eluting beads are used.

In conclusion, regarding TARE treatment, a multidisciplinary team of experts is necessary to ensure the best patient selection and to obtain optimal results; this is possible only in tertiary level centers having certified expertise, after thorough training of the staff.

**REFERENCES**

1 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

2 **Parkin DM**, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*2005; **55**: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]

3 **Bosch FX**, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; **127**: S5-S16 [PMID: 15508102 DOI: 10.1053/j.gastro.2004.09.011]

4 [**European Association For The Study Of The Liver**](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Association%20For%20The%20Study%20Of%20The%20Liver%5BCorporate%20Author%5D), [European Organisation For Research And Treatment Of Cancer](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Organisation%20For%20Research%20And%20Treatment%20Of%20Cancer%5BCorporate%20Author%5D). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

5 **Lencioni R**. Chemoembolization in patients with hepatocellular carcinoma. *Liver Cancer* 2012; **1**: 41-50 [PMID: 24159570 DOI: 10.1159/000339019]

6 **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794]

7 **Kim DY**, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. *Aliment Pharmacol Ther* 2012; **35**: 1343-1350 [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x.]

8 **Sangro B**, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology* 2011; **54**: 868-878 [PMID: 21618574 DOI: 10.1002/hep.24451]

9 **Golfieri R**, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D'Errico-Grigioni A, Pinna AD, Bolondi L. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (& lt; 5 cm) hepatocellular carcinomas. *Hepatology* 2011; **53**: 1580-1589 [PMID: 21351114 DOI: 10.1002/hep.24246]

10 **Golfieri R**, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? *J Vasc Interv Radiol* 2013; **24**: 509-517 [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013]

11 **Takayasu K**, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. *J Hepatol* 2012; **56**: 886-892 [PMID: 22173160 DOI: 10.1016/j.jhep.2011.10.021]

12 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

13 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

14 **Kudo M**, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. *Eur J Cancer* 2011; **47**: 2117-2127 [PMID: 21664811 DOI: 10.1016/j.ejca.2011.05.007]

15 **Kudo M**. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. *Liver Cancer* 2012; **1**: 62-70 [PMID: 24159574 DOI: 10.1159/000342402]

16 **Song T**, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. *Eur J Gastroenterol Hepatol* 2011; **23**: 1233-1238 [PMID: 21941188 DOI: 10.1097/MEG.0b013e32834bd2d0]

17 **Iavarone M**, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. *Hepatology* 2011; **54**: 2055-2063 [PMID: 21898496 DOI: 10.1002/hep.24644]

18 **Kennedy AS**, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. *Int J Radiat Oncol Biol Phys* 2009; **74**: 1494-1500 [PMID: 19157721 DOI: 10.1016/j.ijrobp.2008.10.005]

19 **Wigg AJ**, Palumbo K, Wigg DR. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. *J Gastroenterol Hepatol* 2010; **25**: 664-671 [PMID: 20074152 DOI: 10.1111/j.1440-1746.2009.06126.x.]

20 **Lawrence TS**, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys* 1995; **31**: 1237-1248 [PMID: 7713785 DOI: 10.1016/0360-3016(94)00418-K]

21 **Emami B**, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys* 1991; **21**: 109-122 [PMID: 2032882 DOI: 10.1016/0360-3016(91)90171-Y]

22 **Dawson LA**, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. *J Clin Oncol* 2000; **18**: 2210-2218 [PMID: 10829040]

23 **Dawson LA**, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys* 2002; **53**: 810-821 [PMID: 12095546 DOI: 10.1016/S0360-3016(02)02846-8]

24 **Bilbao JI**, de Martino A, de Luis E, Díaz-Dorronsoro L, Alonso-Burgos A, Martínez de la Cuesta A, Sangro B, García de Jalón JA. Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. *Cardiovasc Intervent Radiol* 2009; **32**: 727-736 [PMID: 19449060 DOI: 10.1007/s00270-009-9592-9]

25 **Sato K**, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S, Nemcek AA, Vogelzang R, Salem R. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. *Cardiovasc Intervent Radiol* 2006; **29**: 522-529 [PMID: 16729228]

26 **MacKie S**, de Silva S, Aslan P, Ladd L, Houang M, Cade D, Delprado W. Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study. *J Urol* 2011; **185**: 285-290 [PMID: 21075399 DOI: 10.1016/j.juro.2010.09.001]

27 **Coldwell D**, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. *Am J Clin Oncol* 2011; **34**: 337-341 [PMID: 20921882 DOI: 10.1097/COC.0b013e3181ec61bb]

28 **Salem R**, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. *J Vasc Interv Radiol* 2006; **17**: 1251-1278 [PMID: 16923973]

29 **Kennedy A**, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. *Am J Clin Oncol* 2012; **35**: 91-99 [PMID: 22363944]

30 **Memon K**, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. *Semin Radiat Oncol* 2011; **21**: 294-302 [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004]

31 **Murthy R**, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. *Radiographics* 2005; **25** Suppl 1: S41-S55 [PMID: 16227496]

32 **Ahmadzadehfar H**, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. *Semin Nucl Med* 2010; **40**: 105-121 [PMID: 20113679 DOI: 10.1053/j.semnuclmed.2009.11.001]

33 **Dezarn WA**, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, Kennedy AS, Nag S, Sarfaraz M, Sehgal V, Selwyn R, Stabin MG, Thomadsen BR, Williams LE, Salem R. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. *Med Phys* 2011; **38**: 4824-4845 [PMID: 21928655]

34 **Salem R**, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A. Research reporting standards for radioembolization of hepatic malignancies. *J Vasc Interv Radiol* 2011; **22**: 265-278 [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029]

35 **Chiesa C**, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, Sposito C, Morosi C, Civelli E, Lanocita R, Camerini T, Bampo C, Bhoori S, Seregni E, Marchianò A, Mazzaferro V, Bombardieri E. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. *Q J Nucl Med Mol Imaging* 2011; **55**: 168-197 [PMID: 21386789]

36 **Sangro B**, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, Chopitea A, Iñarrairaegui M, Arbizu J, Bilbao JI. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. *Cancer* 2008; **112**: 1538-1546 [PMID: 18260156 DOI: 10.1002/cncr.23339]

37 **Leung TW**, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. *Int J Radiat Oncol Biol Phys* 1995; **33**: 919-924 [PMID: 7591903]

38 Sirtex Medical Limited. Sirtex medical training manual, training program physicians and institutions. Australia. Available from: URL: http://www. sirtex.com/usa/\_data/page/549/TRN-US-0320for20US1.pdf

39 **Kennedy A**, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys* 2007; **68**: 13-23 [PMID: 17448867]

40 **Gulec SA**, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. *J Nucl Med* 2006; **47**: 1209-1211 [PMID: 16818957]

41 **Strigari L**, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. *J Nucl Med* 2010; **51**: 1377-1385 [PMID: 20720056 DOI: 10.2967/jnumed.110.075861]

42 **Garin E**, Rolland Y, Boucher E, Ardisson V, Laffont S, Boudjema K, Bourguet P, Raoul JL. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. *Eur J Nucl Med Mol Imaging* 2010; **37**: 453-461 [PMID: 19820932 DOI: 10.1007/s00259-009-1279-6]

43 **Riaz A**, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. *Hepatology* 2009; **49**: 1185-1193 [PMID: 19133645 DOI: 10.1002/hep.22747]

44 **Geschwind JF**, Artemov D, Abraham S, Omdal D, Huncharek MS, McGee C, Arepally A, Lambert D, Venbrux AC, Lund GB. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. *J Vasc Interv Radiol* 2000; **11**: 1245-1255 [PMID: 11099235]

45 **Guo Y**, Yaghmai V, Salem R, Lewandowski RJ, Nikolaidis P, Larson AC, Miller FH. Imaging tumor response following liver-directed intra-arterial therapy. *Abdom Imaging* 2013; **38**: 1286-1299 [PMID: 23807705 DOI: 10.1007/s00261-013-0017-5]

46 **Lencioni R**, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; **30**: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]

47 **Bruix J**, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; **35**: 421-430 [PMID: 11592607]

48 **Carr BI**. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. *Liver Transpl* 2004; **10**: S107-S110 [PMID: 14762849 DOI: 10.1002/lt.20036]

49 **Geschwind JF**, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S194-S205 [PMID: 15508085 DOI: 10.1053/j.gastro.2004.09.034]

50 **Salem R**, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. *J Vasc Interv Radiol* 2005; **16**: 1627-1639 [PMID: 16371529 DOI: 10.1097/01.RVI.0000184594.01661.81]

51 **Salem R**, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. *J Vasc Interv Radiol* 2002; **13**: S223-S229 [PMID: 12354840 DOI: 10.1016/S1051-0443(07)61790-4]

52 **Steel J**, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). *Psychooncology* 2004; **13**: 73-79 [PMID: 14872525 DOI: 10.1002/pon.725]

53 **Liu MD**, Uaje MB, Al-Ghazi MS, Fields D, Herman J, Kuo JV, Milne N, Nguyen TH, Ramsinghani NS, Tokita KM, Tsai FY, Vajgrt DJ, Imagawa DK. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. *Am Surg* 2004; **70**: 947-953 [PMID: 15586503]

54 **Lau WY**, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. *Int J Radiat Oncol Biol Phys* 1998; **40**: 583-592 [PMID: 9486608 DOI: 10.1016/S0360-3016(97)00818-3]

55 **Hilgard P**, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. *Hepatology* 2010; **52**: 1741-1749 [PMID: 21038413 DOI: 10.1002/hep.23944]

56 **Mazzaferro V**, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. *Hepatology* 2013; **57**: 1826-1837 [PMID: 22911442 DOI: 10.1002/hep.26014]

57 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]

58 **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]

59 **Cammà C**, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* 2002; **224**: 47-54 [PMID: 12091661 DOI: 10.1148/radiol.2241011262]

60 **Chen CH**, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. *Eur J Cancer* 2009; **45**: 1630-1639 [PMID: 19157858 DOI: 10.1016/j.ejca.2008.12.025]

61 **Lewandowski RJ**, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA, Vogelzang RL, Omary RA, Benson AB, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. *Radiology* 2010; **255**: 955-965 [PMID: 20501733 DOI: 10.1148/radiol.10091473]

62 **Wang JH**, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. *Eur J Cancer* 2008; **44**: 1000-1006 [PMID: 18337087 DOI: 10.1016/j.ejca.2008.02.018]

63 **Salem R**, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 497-507.e2 [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049]

64 **Lance C**, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2011; **22**: 1697-1705 [PMID: 21983055 DOI: 10.1016/j.jvir.2011.08.013]

65 **Bolondi L**, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. *Semin Liver Dis* 2012; **32**: 348-359 [PMID: 23397536 DOI: 10.1055/s-0032-1329906]

66 **Riaz A**, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. *J Vasc Interv Radiol* 2009; **20**: 1121-1130; quiz 1131 [PMID: 19640737 DOI: 10.1016/j.jvir.2009.05.030]

67 **Riaz A**, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH, Sato KT, Omary RA, Abecassis M, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. *Cardiovasc Intervent Radiol* 2010; **33**: 1143-1152 [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5]

68 **Carr BI**, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. *Cancer* 2010; **116**: 1305-1314 [PMID: 20066715 DOI: 10.1002/cncr.24884]

69 **Lewandowski RJ**, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant* 2009; **9**: 1920-1928 [PMID: 19552767 DOI: 10.1111/j.1600-6143.2009.02695.x]

70 [**Gramenzi A**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gramenzi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Golfieri R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Golfieri%20R%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Mosconi C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mosconi%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Cappelli A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cappelli%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Granito A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Granito%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Cucchetti A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cucchetti%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Marinelli S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Marinelli%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Pettinato C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Pettinato%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Erroi V](http://www.ncbi.nlm.nih.gov/pubmed/?term=Erroi%20V%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Fiumana S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fiumana%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Bolondi L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bolondi%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Bernardi M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bernardi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24750853), [Trevisani F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Trevisani%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24750853); [BLOG (Bologna Liver Oncology Group)](http://www.ncbi.nlm.nih.gov/pubmed/?term=BLOG%20(Bologna%20Liver%20Oncology%20Group)%5BCorporate%20Author%5D). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver Int* 2014; Epub ahead of print [PMID: 24750853 DOI: 10.1111/liv.12574]

71 **Salem R**, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; **138**: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006]

72 **Sangro B**, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. *J Hepatol* 2012; **56**: 464-473 [PMID: 21816126 DOI: 10.1016/j.jhep.2011.07.012]

73 **Rana N**, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. *Front Oncol* 2013; **3**: 323 [PMID: 24416722 DOI: 10.3389/fonc.2013.00323]

74 **Chow PK**, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. *PLoS One* 2014; **9**: e90909 [PMID: 24614178 DOI: 10.1371/journal.pone.0090909]

75 **Kulik L**, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. *J Hepatol* 2014; **61**: 309-317 [PMID: 24681342 DOI: 10.1016/j.jhep.2014.03.023]

76 **Lau WY**, Leung WT, Ho S, Leung NW, Chan M, Lin J, Metreweli C, Johnson P, Li AK. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. *Br J Cancer* 1994; **70**: 994-999 [PMID: 7947110 DOI: 10.1038/bjc.1994.436]

77 **Cao X**, He N, Sun J, Tan J, Zhang C, Yang J, Lu T, Li J. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. *Chin Med J* (Engl) 1999; **112**: 430-432 [PMID: 11593513]

78 **Kennedy AS**, Coldwell D, Nutting C, Murthy R, Wertman DE, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. *Int J Radiat Oncol Biol Phys* 2006; **65**: 412-425 [PMID: 16690429 DOI: 10.1016/j.ijrobp.2005.12.051]

79 **Atassi B**, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R. Biliary sequelae following radioembolization with Yttrium-90 microspheres. *J Vasc Interv Radiol* 2008; **19**: 691-697 [PMID: 18440457 DOI: 10.1016/j.jvir.2008.01.003]

80 **Young JY**, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, Larson AC, Ryu RK, Sato KT, Lewandowski RJ, Omary RA, Salem R. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. *J Vasc Interv Radiol* 2007; **18**: 1375-1382 [PMID: 18003987]

81 **Golfieri R**, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. *J Hepatol* 2013; **59**: 753-761 [PMID: 23707371 DOI: 10.1016/j.jhep.2013.05.025]

82 **Jelic S**, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; **21** Suppl 5: v59-v64 [PMID: 20555104 DOI: 10.1093/annonc/mdq166]

83 National comprehensive cancer network clinical practice guidelines in oncology. Hepatobiliary guidelines. V2.2010. Available from: URL: http://www.ncccn. org/professionals/physician\_gls/PDF/hepatobiliary.pdf

84 **Thomas MB**, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. *J Clin Oncol* 2010; **28**: 3994-4005 [PMID: 20679622 DOI: 10.1200/JCO.2010.28.7805]

85 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

86 **Salem R**, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. *Clin Gastroenterol Hepatol* 2013; **11**: 1358-1365.e1 [PMID: 23644386 DOI: 10.1016/j.cgh.2013.04.028]

87 **Heffernan N**, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. *J Clin Oncol* 2002; **20**: 2229-2239 [PMID: 11980994]

88 **Kooby DA**, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA, Kim HS. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2010; **21**: 224-230 [PMID: 20022765 DOI: 10.1016/j.jvir.2009.10.013]

89 **Kim YH**, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. *Oncology* 2013; **84** Suppl 1: 34-39 [PMID: 23428856 DOI: 10.1159/000345887]

90 **Okuda K**, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer* 1985; **56**: 918-928 [PMID: 2990661]

91 **Sangro B**, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2006; **66**: 792-800 [PMID: 16904840]

92 **Kulik LM**, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; **47**: 71-81 [PMID: 18027884]

93 **Lau WY**, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. *Oncology* 2013; **84**: 311-318 [PMID: 23615394 DOI: 10.1159/000348325]

94 **Iñarrairaegui M**, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol* 2010; **21**: 1205-1212 [PMID: 20598574 DOI: 10.1016/j.jvir.2010.04.012]

95 **Tsai AL**, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol* 2010; **21**: 1377-1384 [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027]

96 **Woodall CE**, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? *J Am Coll Surg* 2009; **208**: 375-382 [PMID: 19317999 DOI: 10.1016/j.jamcollsurg.2008.12.009]

**P- Reviewer:** Bilir C, FarrisAB **S- Editor:** Gong XM

**L- Editor:** **E- Editor:**

**Table 1 Characteristics of commercially available 90Y-microspheres for transarterial radioembolization (modified from[72])**

|  |  |  |
| --- | --- | --- |
|  | **SIR-Spheres1** | **TheraSphere2** |
| Isotope 90Y | Attached to the surface | Incorporated into the glass matrix |
| Half-life (h) | 64.1 | 64.1 |
| Microsphere material | Resin | Glass |
| Microsphere diameter (μm)  Average size (μm) | 20–60  32.5 | 20–30  25 |
| Approximate activity per microsphere (Bq) | 50 | 2500 |
| Number of microspheres per 3 GBq | 40–80 x 106 | 1.2 x 106 |
| Specific gravity (g/mL) | 1.6 | 3.6 |
| Activity per commercially available vial (GBq) | 3 (can be divided) | 3, 5, 7, 10, 15, 20 |
| Activity calculation | Compartmental MIRD macrodosimetry or empirical formula based on liver volume and tumor volume | Non-compartmental MIRD macrodosimetry |
| Estimated dose to the central vein area (Gy) in the Montecarlo simulation3 | 59 | 58 |
| Embolic effect | Moderate | Mild |
| Contrast agent injection | During infusion | None |
| Indication | United States (FDA PMA): colorectal liver metastases | United States (FDA HDE): hepatocellular carcinoma |

1Sirtex Medical, North Sydney, Australia; 2BTG International Canada Inc., Ottawa, Ontario, Canada. TARE: Transarterial radioembolization; MIRD: Medical Internal Radiation Dosimetry; FDA: Food and Drug Administration; PMA: Pre-Market Approval; HDE: Humanitarian Device Exemption. 3from Gulec *et al*[40].

**Table 2 Outcomes after transarterial radioembolization from recent studies (modified from[89])**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **No. of patients** | **Response rate** | **Survival (mo)** | **Prognostic factors** |
| Carr *et al*[48] | 65 | OR 38% | Okuda[90] I: 21  Okuda[90] II:10 |  |
| Salem *et al*[50] | 43 | PR 47% | Okuda[90] I: 24  Okuda[90] II:13 | Main PVTT; AFP > 400 ng/mL  tumor burden > 25% |
| Sangro *et al*[91] | 24 | PR 24%; SD 64% | 7 |  |
| Young *et al*[80] | 41 |  | Okuda[90] I: 21.7  Okuda[90]II: 14.2 |  |
| Kulik *et al*[92] | 71 | PR 42%; SD 35% | 15.5 |  |
| Salem *et al*[63] | 123 | RR 72% | 20.5 | Sex (female); Child-Pugh class; UNOS |
| Sangro *et al*[8] | 325 |  | 12.8 | ECOG; nodules > 5; INR > 1.2; extrahepatic disease |
| Mazzaferro *et al*[56] | 52 | CR 9.6%; OR 40.4% | 15 | Response; Child Pugh class |

PVTT: Portal vein tumour thrombosis; AFP: Alpha-fetoprotein; OR: Odds ratio; PR: Partial response; RR: Response rate; CR: Complete response; SD: Stable disease; UNOS: United Network of Organ Sharing; ECOG: European Cooperative Oncology Group; INR: International Normalized Ratio.

**Table 3 Comparison of response and median survival after transarterial radioembolization and transarterial chemoembolization from recent studies (modified from[93])**


|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Treatment** | **N.** | **OS (months)** | **TTP (months)** | **Response (CP/PR) %**  **WHO/RECIST**  **criteria** | **RR (CP/PR)**  **%**  **EASL**  **criteria** | **Downstaged/LT**  **%** | **Mean days in hospital per treatment** |
| Lewandowski *et al*[69] | TARE (TheraSphere1)  TACE | 43  43 | 35.7  18.7 | 33.3  18.2 | 61  37 | 86  71 | 58a  31 | 0 a  3 |
| Kooby *et al*[88] | TARE (SIR-Spheres2)  TACE | 27  44 | 6  6 | NR | 11  6 | NR | NR | 1.7 a  6 |
| Carr *et al*[68] | TARE (TheraSphere1)  TACE | 99  691 | 11.5  8.5 | NR | 41  60 | NR | NR | NR |
| Salem *et al*[63] | TARE (TheraSphere1)  TACE | 123  122 | 20.5  17.4 | 13.3  8.4 | 49  46 | 72  69 | 25  36 | 0 a  1.8 |


1BTG International Canada Inc., Ottawa, Ontario, Canada; 2Sirtex Medical, North Sydney, Australia. a*P* < 0.05. OS: Overall survival; TTP: Time to tumor progression; CP: Complete response; PR: Partial response; RR: Response rate; WHO: World Health Organization tumor response criteria; RECIST: Response Evaluation Criteria in solid tumors; TARE: Transarterial radioembolization; TACE: Transarterial chemoembolization; EASL: European Association for the Study of the Liver; LT: Liver transplantation; NR: Not reported.


**Table 4 Response and median survival after transarterial radioembolization in hepatocellular carcinoma with or without portal vein tumour thrombosis from recent studies (modified from[90])**


|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **PVTT** | **N** | **Response (CR/PR) %**  **WHO/RECIST**  **criteria** | **RR (CR/PR) %**  **EASL criteria** | **OS** |
| Salem *et al*[71]  TheraSphere1  no EHS | Child-Pugh A  No PVTT  PVTT (mixed)  First-order  Main | 116  81  35  19  16 | 52  53  50  58  40 | 69  77  50  58  40 | 17.2  22.1  10.4  16.6  7.7 |
| Child-Pugh B  No PVTT  PVTT (mixed)  First-order  Main | 122  65  57  27  30 | 39  47  28  28  28 | 52  67  32  40  24 | 7.7  14.8  5.6  6.5  4.5 |
| Hilgard *et al*[55]  TheraSphere1  30% EHS | All pts  No PVTT  PVTT [mixed: main (12);  First/second order (12); unknown (9)] | 108  75  33 | 15  NR | 40  NR | 16.4  16.4  10 |
| Sangro *et al*[8]  SIR-Spheres2  9% EHS | All pts  No PVTT  PVTT [mixed: main (32);  First order (44)] | 325  249  76 | NR | NR | 12.8  15.3  10.7  9.7 |
| Iñarrairaegui *et al*[94]  TheraSphere1 and SIR-Spheres2 | PVTT [mixed: main (6);  First/second order (19)] | 25 | NR | NR | 10 |
| Tsai *et al*[95]  TheraSphere1 and SIR-Spheres2  13% EHS | PVTT  Main  First order | 22  12  10 | NR | NR | 7  4.4  7 |
| Woodall *et al*[96]  TheraSphere1 | No PVTT  PVTT [mixed: main (10)] | 20  15 | NR | NR | 13.9  3.2 |
| Kulik *et al*[92]  TheraSphere1  12%EHS | All pts  No PVTT  PVTT main  first order | 108  71  12  25 | 42 | 70 | NR  15.4  4.4  9.9 |

1BTG International Canada Inc., Ottawa, Ontario, Canada; 2Sirtex Medical, North Sydney, Australia. PVTT: Portal Vein Tumor Thrombosis; CR: Complete response; PR: Partial response; WHO: World Health Organization tumor response criteria; RECIST: Response Evaluation Criteria in solid tumors; RR: Response rate; EASL: European Association for the Study of the Liver; TARE: Transarterial radioembolization; HCC: Hepatocellular carcinoma; RECIST: Response Evaluation Criteria in solid tumors; EHS: Extrahepatic Disease; NR: Not reported; OS: Overall survival; Main: Main portal vein trunk; First order: Right and/or left portal vein; Second order: Segmental branches of portal vein.

****

** **

****

****

**Figure 1 Treatment with yttrium-90 and response of infiltrative hepatocellular carcinoma.** A-B: The pretreatment computed tomography (CT) showing infiltrative hepatocellular carcinoma in the IV segment with associated tumor thrombosis of the left portal branch as visualized in the arterial phase and in the portal-venous phase; C: The pretreatment angiogram carried out with selective catheterization of the left hepatic artery, arising from the left gastric artery, confirms the hypervascularization of the venous thrombus; D: The pretreatment 99mTc-MAA single photon emission computed tomography images showing the corresponding uptake of MAA in the region of interest (tumor thrombus); E-F: The CT performed 1 mo after treatment showing both a significant decrease of the enhancement of the portal venous thrombus and a reduction in the enlargement of the portal branch as a sign of response, better visualized at 1 year (G-H). Note the significant “shrinkage” of the left lobe and the compensatory hypertrophy of the contralateral hepatic lobe.